🔗 Permalink

Assignee profile:

INFLARX GMBH

City:

Jena

Country:

Germany

Published Applications:

Last publication date:

2024-11-28

Patent Grants:

Last grant date:

2024-12-31

Top Inventors for applications by INFLARX GMBH

These are the the leading inventors for applications assigned to INFLARX GMBH:

Renfeng GUO 16 Ann Arbor, MI United States
Niels Christoph RIEDEMANN 7 Jena, Germany
Niels C. Riedemann 5 Jena, Germany
Yan Li 3 Beijing, China

YONG LI 3 ANN ARBOR, MI United States
Beifen SHEN 3 Beijing, China
Niels Christoph RIEDEMANN 2 Jeny, Germany
Niels R. Riedemann 2 Jena, Germany

Niels Cristoph RIEDEMANN 1 Jena, Germany
Yan LI 1 Bejiing, China
Beifen SHEN 1 Bejing, China
Yan Li 1 Bejing, China

Niels Christoph Reidemann 1 Jena, Germany

Recent patent applications by INFLARX GMBH

INFLARX GMBH based in Jena, DE has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2024-11-28 ✅ Patent 12,180,274 granted on 2024-12-31

US20240391995A1

Chemistry; metallurgy

Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

#2 | 2024-09-12

US20240300898A1

Chemistry; metallurgy

FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR

#3 | 2023-09-07 ✅ Patent 12,606,613 granted on 2026-04-21

US20230279087A1

Chemistry; metallurgy

HUMANIZED ANTI-C5A ANTIBODIES

#4 | 2023-05-25

US20230158060A1

Human necessities

Inhibitors of C5a for the Treatment of Corona Virus Infection

#5 | 2021-12-30 ✅ Patent 11,999,698 granted on 2024-06-04

US20210403433A1

Chemistry; metallurgy

Fused piperidinyl bicyclic and related compounds as modulators of C5a receptor

#6 | 2021-02-18 ✅ Patent 11,890,349 granted on 2024-02-06

US20210046191A1

Human necessities

Treatment of inflammatory diseases with inhibitors of C5A activity

#7 | 2020-09-17 ✅ Patent 11,149,009 granted on 2021-10-19

US20200290969A1

Chemistry; metallurgy

Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor

#8 | 2020-02-27 ✅ Patent 11,464,868 granted on 2022-10-11

US20200061202A1

Human necessities

Treatment of inflammatory diseases with inhibitors of C5A activity

#9 | 2019-07-04 ✅ Patent 10,858,421 granted on 2020-12-08

US20190202900A1

Chemistry; metallurgy

Inhibitors of C5A for the treatment of viral pneumonia

#10 | 2018-10-04 ✅ Patent 11,273,225 granted on 2022-03-15

US20180282425A1

Chemistry; metallurgy

Treatment of inflammatory diseases with inhibitors of C5a activity

#11 | 2018-10-04 ✅ Patent 10,376,595 granted on 2019-08-13

US20180280530A1

Human necessities

Treatment of inflammatory diseases with inhibitors of C5a activity

#12 | 2017-05-18 ✅ Patent 10,227,397 granted on 2019-03-12

US20170137499A1

Chemistry; metallurgy

Inhibitors of C5a for the treatment of viral pneumonia

#13 | 2017-01-05 ✅ Patent 10,774,136 granted on 2020-09-15

US20170002067A1

Chemistry; metallurgy

Anti-C5a binding moieties with high blocking activity

#14 | 2015-09-24 ✅ Patent 9,458,233 granted on 2016-10-04

US20150266949A1

Chemistry; metallurgy

Anti-C5a binding moieties with high blocking activity

#15 | 2014-10-23 ✅ Patent 9,073,983 granted on 2015-07-07

US20140314772A1

Chemistry; metallurgy

Anti-C5A binding moieties with high blocking activity

#16 | 2012-09-13 ✅ Patent 8,802,096 granted on 2014-08-12

US20120231008A1

Chemistry; metallurgy

Anti-C5a binding antibodies with high block activity

Also check out InflaRx GmbH's (Jena, Germany) applicant profile with 14 patent applications submitted.

AssigneeID:

122205 ⎘